Envista (NVST) Projected to Post Quarterly Earnings on Thursday

Envista (NYSE:NVST) is projected to announce its Q2 2025 earnings results after the market closes on Thursday, July 31st. Analysts expect the company to announce earnings of $0.24 per share and revenue of $638.21 million for the quarter. Envista has set its FY 2025 guidance at 0.950-1.050 EPS.

Envista (NYSE:NVST) last announced its quarterly earnings results on Thursday, May 1st. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.04. Envista had a positive return on equity of 4.07% and a negative net margin of 44.90%. The business had revenue of $616.90 million during the quarter, compared to analyst estimates of $608.17 million. During the same period in the previous year, the company earned $0.26 EPS. The firm’s revenue was down 1.1% on a year-over-year basis. On average, analysts expect Envista to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Envista Trading Down 2.0%

NYSE:NVST opened at $20.32 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.82 and a current ratio of 2.12. The company has a market capitalization of $3.44 billion, a P/E ratio of -3.11, a P/E/G ratio of 1.31 and a beta of 1.00. The stock’s 50 day moving average price is $19.23 and its 200 day moving average price is $18.59. Envista has a 52 week low of $14.22 and a 52 week high of $23.00.

Wall Street Analysts Forecast Growth

NVST has been the subject of a number of analyst reports. UBS Group boosted their price target on Envista from $18.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday. Morgan Stanley set a $16.00 target price on Envista in a research report on Tuesday, April 15th. Bank of America lowered their price target on Envista from $26.00 to $23.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Robert W. Baird upgraded shares of Envista from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $21.00 to $23.00 in a research note on Tuesday, May 27th. Finally, Baird R W upgraded shares of Envista from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 27th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $20.54.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in NVST. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Envista by 15.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 568,982 shares of the company’s stock valued at $9,821,000 after purchasing an additional 76,246 shares during the period. Goldman Sachs Group Inc. raised its stake in Envista by 39.3% during the first quarter. Goldman Sachs Group Inc. now owns 629,140 shares of the company’s stock worth $10,859,000 after acquiring an additional 177,630 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Envista by 218.6% during the first quarter. Millennium Management LLC now owns 383,966 shares of the company’s stock valued at $6,627,000 after acquiring an additional 263,442 shares during the period. Finally, Royal Bank of Canada grew its holdings in shares of Envista by 26.6% in the 1st quarter. Royal Bank of Canada now owns 23,240 shares of the company’s stock worth $401,000 after purchasing an additional 4,885 shares during the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.